

Cover Story
Free
This series re-examines the concurrent controversies at the Cancer Prevention and Research Institute of Texas and MD Anderson Cancer Center. This examination is possible in part because of new insight provided by Alfred Gilman, the Nobel laureate who served as the first scientific director of the state institution that distributes $300 million a year. Gilman died on Dec. 23, 2015.
In Brief


Drugs & Targets
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- Pour a Scotch, we’re talking clinical trials and prediction markets
- Consumers are increasingly accessing U.S. News rankings of cancer hospitals via AI chatbots
2026 report shows no change in the top-five lineup - FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial - The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access











